Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A10BD08

Icandra (previously Vildagliptin / metformin hydrochloride Novartis)(vildagliptin;metformin hydrochloride)

Diabetes Mellitus, Type 2

Marketing Authorisation Holder: Novartis Europharm Limited

EMA Authorisation: 30/11/2008

INN: vildagliptin;metformin

Indication

Icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Icandra (previously Vildagliptin / metformin hydrochloride Novartis) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.